Related Experiment Videos
The need for flexibility in dosing of hypnotic agents
1Sleep Disorders Center, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA. Karl.Doghramji@mail.tju.edu
Sleep
|February 7, 2001
Summary
For intermittent insomnia, zaleplon is a suitable hypnotic for middle-of-the-night use due to its rapid onset and short half-life, with minimal residual effects or rebound insomnia compared to other agents.
Area of Science:
- Pharmacology
- Sleep Medicine
- Clinical Therapeutics
Background:
- Insomnia is common, often with unknown causes, necessitating symptomatic treatment.
- Intermittent insomnia is best managed with as-needed hypnotic medication.
- Benzodiazepine receptor agonists (BzRAs) are frequently used for insomnia treatment.
Purpose of the Study:
- To evaluate hypnotic agents for intermittent insomnia treatment.
- To identify agents suitable for middle-of-the-night administration.
- To compare the safety and efficacy profiles of zaleplon, zolpidem, and other BzRAs.
Main Methods:
- Review of pharmacokinetic properties of BzRAs.
- Analysis of clinical trial data on residual sedation and rebound insomnia.
- Comparison of zaleplon, zolpidem, and flurazepam in placebo-controlled trials.
Main Results:
- Zaleplon has a rapid onset and short half-life (1 hour), ideal for middle-of-the-night dosing.
- Zaleplon showed no residual sedation or rebound insomnia in trials.
- Zolpidem demonstrated transient rebound insomnia, unlike zaleplon.
Conclusions:
- Zaleplon is a preferred option for intermittent insomnia requiring middle-of-the-night dosing.
- Consideration of psychomotor impairment and rebound insomnia is crucial in agent selection.
- Further research is needed on long-term intermittent hypnotic therapy.